when will tirzepatide get fda approval Wins for Weight Loss Big update in pediatric diabetes

Do not push it further by allowing additional room temperature time

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentration in routine clinical care

Novo Nordisk said in a statement that the acquisition will increase the companys production capacity beginning in 2026

Ziegler D, Hanefeld M, Ruhnau K, et al

On June 2025, Camurus and Eli Lilly and Company have signed a collaboration and license agreement that gives Lilly exclusive worldwide rights to the research, development, manufacturing, and commercialization of long-acting incretin medicines for cardiometabolic health based on Camurus FluidCrystal technology